C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT8634 for the treatment of soft tissue sarcoma.
https://finance.yahoo.com/news/c4-therapeutics-announces-fda-orphan-130000637.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.